Neuland Laboratories Limited

Neuland Laboratories Limited

Neuland Laboratories Limited has commenced commercial production at two additional capacities under its expansion plans at its units in Telangana, India.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about the schedule of its Q1 FY 2027 Earnings Call, to be held on August 05, 2026, at 17:30 Hrs (IST).

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Loss of Share Certificates. A shareholder has reported the loss of their share certificate(s) and requested for issuance of entitlement letter or direct credit of shares.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about the affirmation of its credit rating by India Ratings and Research.

Neuland Laboratories Limited

Neuland Laboratories Limited has published a newspaper advertisement regarding the dispatch of notice of its 42nd Annual General Meeting and Integrated Annual Report for FY 2025-26.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding 'Letter to the Shareholders of the Company in relation to the Notice of 42nd Annual General Meeting and the Integrated Annual Report of the Company for FY 2025-26'.

Neuland Laboratories Limited

Neuland Laboratories Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as required by the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 04, 2026. The meeting will consider and adopt the Audited Financial Statements for the financial year ended March 31, 2026, and the Audited Consolidated Financial Statements for the financial year ended March 31, 2026. The meeting will also consider the appointment of Dr. Mauricio Futran as Non-Executive Non-Independent Director of the Company, and the payment of commission to the Non-executive Directors of the Company.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in the equity shares of the Company shall remain closed from July 1, 2026, till 48 hours after the declaration of financial results for the quarter ended June 30, 2026.